M/s. Genix Pharma (Pvt) Ltd.
Private pharmaceutical manufacturer · Karachi · Pakistan
Pharmaceutical manufacturer founded in 2004 with a broad portfolio of prescription and OTC medicines and an export presence.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Genix Pharma (Private) Limited
- Company type
- Private pharmaceutical manufacturer
- Address
- 44, 45-B, Korangi Creek Road, Karachi-75190, Pakistan · 75190
- Website
- genixpharma.com.pk ↗
- Phone
- +92 21 111 10 10 11
- info@genixpharma.com
- Official contact
- Contact page ↗
- Official company profile ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Gentrop | Tiotropium | 18 mcg | Capsule | 6's | 086941 | PKR 205.98 | PKR 34.33/capsule | Near median |
| Gentrop | Tiotropium | 18 mcg | Capsule | 15's | 086941 | PKR 485.62 | PKR 32.37/capsule | Near median |
| Gentrop | Tiotropium | 18 mcg | Capsule | 20's | 086941 | PKR 634.28 | PKR 31.71/capsule | Near median |
| Gentrop | Tiotropium | 18 mcg | Capsule | 30's | 086941 | PKR 951.42 | PKR 31.71/capsule | Near median |
| Hadzone | Ceftriaxone | 250 mg | Powder for IV injection | 1'S | 103082 | PKR 186.50 | PKR 186.50/vial/unit | No comparator |
| Hadzone | Ceftriaxone | 250 mg | Powder for injection | 1'S | 103082 | PKR 186.50 | PKR 186.50/vial/unit | Near median |
| Hadzone | Ceftriaxone | 250 mg | Powder for IM injection | 1'S | 103083 | PKR 186.50 | PKR 186.50/vial/unit | No comparator |
| Hadzone | Ceftriaxone | 250 mg | Powder for injection | 1'S | 103083 | PKR 186.50 | PKR 186.50/vial/unit | Near median |
| Hadzone | Ceftriaxone | 500 mg | Powder for IV injection | 1'S | 103084 | PKR 313.93 | PKR 313.93/vial/unit | Near median |
| Hadzone | Ceftriaxone | 500 mg | Powder for injection | 1'S | 103084 | PKR 313.93 | PKR 313.93/vial/unit | Near median |
| Hadzone | Ceftriaxone | 500 mg | Powder for IM injection | 1'S | 103085 | PKR 313.93 | PKR 313.93/vial/unit | 40% above median |
| Hadzone | Ceftriaxone | 500 mg | Powder for injection | 1'S | 103085 | PKR 313.93 | PKR 313.93/vial/unit | Near median |
| Hadzone | Ceftriaxone | 1 g | Powder for IV injection | 1'S | 103086 | PKR 592.76 | PKR 592.76/vial/unit | 34% below median |
| Hadzone | Ceftriaxone | 1 g | Powder for injection | 1'S | 103086 | PKR 592.76 | PKR 592.76/vial/unit | Near median |
| Hadzone | Ceftriaxone | 2 g | Injection | Vial | 123350 | PKR 929.37 | PKR 929.37/vial/unit | 15% above median |
| Haemic | Tranexamic acid | 500 mg/5 mL | Injection | 10 x 5ml | 073461 | PKR 829.10 | PKR 16.58/mL | 34% below median |
| Haemic | Tranexamic acid | 250 mg/5 mL | Injection | 10's | 083921 | PKR 963.02 | PKR 96.30/vial/unit | 58% above median |
| Haemic | Tranexamic acid | 1000 mg/10 mL | Injection | 5 x 10ml | 089081 | PKR 1,412.22 | PKR 28.24/mL | No comparator |
| Halod | Haloperidol | 5 mg | Tablet | 100's | 083922 | PKR 181.97 | PKR 1.82/tablet | Near median |
| Halod | Haloperidol | 10 mg | Tablet | 50's | 083923 | PKR 178.38 | PKR 3.57/tablet | Near median |
| Ifedip PR | Nifedipine | 30 mg | Prolonged-release tablet | 2 X 10's | 108623 | PKR 684.66 | PKR 34.23/tablet | No comparator |
| Ifedip PR | Nifedipine | 20 mg | Tablet | 3 X 10's | 108624 | PKR 684.66 | PKR 22.82/tablet | No comparator |
| Ifedip PR | Nifedipine | 60 mg | Prolonged-release tablet | 2 X 10's | 108625 | PKR 1,141.11 | PKR 57.06/tablet | No comparator |
| Ir-Chel | Deferasirox | 500 mg | Oral suspension | 4x7's | 137122 | PKR 7,280.00 | PKR 260.00/unit | No comparator |
| Ir-Chel | Deferasirox | 125 mg | Oral suspension | 4x7's | 137123 | PKR 2,649.00 | PKR 94.61/unit | No comparator |
| Ir-Chel | Deferasirox | 250 mg | Oral suspension | 4x7's | 137124 | PKR 4,386.00 | PKR 156.64/unit | No comparator |
| Itracap | Itraconazole | 100 mg | Capsule | 4's | 023528 | PKR 538.43 | PKR 134.61/capsule | 8% below median |
| Itramide | Ipratropium bromide | 20 mcg | Metered-dose inhaler | Inhaler of 200mds/actuations | 127798 | PKR 898.41 | — | No comparator |
| Itramide Nebulization | Ipratropium bromide | 0.5 mg/2 mL | Nebuliser solution | 5x2ml | 123348 | PKR 429.01 | PKR 42.90/mL | 32% below median |
| Ivermec | Ivermectin | 3 mg | Tablet | 20's | 070684 | PKR 682.48 | PKR 34.12/tablet | 7% above median |
| Ivermec | Ivermectin | 6 mg | Tablet | 20's | 112712 | PKR 1,066.36 | PKR 53.32/tablet | Near median |
| Ivermec | Ivermectin | 6 mg | Tablet | 10's | 112712 | PKR 565.17 | PKR 56.52/tablet | Near median |
| Karmol | Paracetamol | 500 mg | Tablet | 20 x 10's | 022114 | PKR 742.12 | PKR 3.71/tablet | Near median |
| Karmol | Paracetamol | 120 mg/5 mL | Suspension | 60mL | 022115 | PKR 60.49 | PKR 1.01/mL | Near median |
| Karmol | Paracetamol | 250 mg/5 mL | Suspension | 5's | 120148 | PKR 41.31 | PKR 8.26/unit | No comparator |
| Karmol | Paracetamol | 125 mg | Suppository | 5's | 120149 | PKR 30.98 | PKR 6.20/suppository | 12% above median |
| Karoxyn | Doxycycline | 100 mg | Capsule | 1's | 015137 | PKR 10.44 | PKR 10.44/capsule | 33% above median |
| Lamgin | Lamotrigine = | 25 mg | Tablet | 3 x 10's | 039033 | PKR 648.64 | PKR 21.62/tablet | Near median |
| Lamgin | Lamotrigine = | 50 mg | Tablet | 3 x 10's | 039034 | PKR 864.89 | PKR 28.83/tablet | Near median |
| Lamgin | Lamotrigine = | 100 mg | Tablet | 3 x 10's | 039035 | PKR 1,081.10 | PKR 36.04/tablet | Near median |
| Lamgin | Lamotrigine = | 150 mg | Tablet | 3 x 10's | 039036 | PKR 1,297.32 | PKR 43.24/tablet | 5% above median |
| Lamgin | Lamotrigine = | 200 mg | Tablet | 3 x 10's | 039037 | PKR 1,513.54 | PKR 50.45/tablet | Near median |
| Larith | Clarithromycin | 125 mg/5 mL | Dry suspension | 60ml | 057874 | PKR 460.56 | PKR 7.68/mL | 6% above median |
| Larith | Clarithromycin | 250 mg | Tablet | 10's | 057875 | PKR 511.85 | PKR 51.19/tablet | 8% above median |
| Larith | Clarithromycin | 500 mg | Tablet | 10's | 057876 | PKR 919.05 | PKR 91.91/tablet | 10% above median |
| Larith | Clarithromycin | 125 mg/mL | Oral drops | 25ml | 070529 | PKR 192.07 | PKR 7.68/mL | No comparator |
| Larith | Clarithromycin | 500 mg | IV infusion | 1Vial | 073692 | PKR 170.61 | PKR 170.61/vial/unit | 41% below median |
| Larith | Clarithromycin | 250 mg/5 mL | Oral suspension | 60ml | 092882 | PKR 729.42 | PKR 12.16/mL | Near median |
| Larith XL | Clarithromycin | 500 mg | Tablet | 5's | 067328 | PKR 427.52 | PKR 85.50/tablet | Near median |
| Larith XL | Clarithromycin | 500 mg | Tablet | 1's | 067328 | PKR 92.94 | PKR 92.94/tablet | 11% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.
